<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The prevalence of <z:hpo ids='HP_0003774'>end-stage renal disease</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e>) is uprising in the paralleled with the increase of <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:e sem="disease" ids="C0022658" disease_type="Disease or Syndrome" abbrv="">kidney disease</z:e> (CKD) patients </plain></SENT>
<SENT sid="1" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>nephropathy</z:hpo> (DN) is the most important underlying disease of CKD and a leading cause of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> in Japan </plain></SENT>
<SENT sid="2" pm="."><plain>Intensified multifactorial intervention in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> with <z:mp ids='MP_0002959'>microalbuminuria</z:mp> slows the progression to <z:hpo ids='HP_0000112'>nephropathy</z:hpo>, and progression of <z:hpo ids='HP_0000488'>retinopathy</z:hpo> and <z:e sem="disease" ids="C0259749" disease_type="Disease or Syndrome" abbrv="">autonomic neuropathy</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>However, further studies are needed to establish the effect of intensified multifactorial treatment on DN with overt <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="4" pm="."><plain>In this trial, doctors and co-medicals collaborate to treat the DN patients to prevent the deterioration of DN by multifactorial intensive therapy </plain></SENT>
<SENT sid="5" pm="."><plain>Diabetic <z:hpo ids='HP_0000112'>Nephropathy</z:hpo> Remission and Regression Team Trial in Japan (DNETT-Japan) is an open, randomized controlled trial to evaluate the efficacy of renal protection of multifactorial intensive therapy in type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> patients with overt <z:hpo ids='HP_0000093'>proteinuria</z:hpo> (urinary albumin-to-<z:chebi fb="0" ids="16737">creatinine</z:chebi> ratio &gt; or =300 mg/g <z:chebi fb="0" ids="16737">creatinine</z:chebi>) </plain></SENT>
<SENT sid="6" pm="."><plain>The study has a targeted enrollment of 600 Japanese patients, and divided into two protocols by <z:hpo ids='HP_0000083'>renal insufficiency</z:hpo> (protocol A: serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>: &lt;1.2mg/dl in male and &lt;1.0mg/dl in female, and protocol B: serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>: 1.2-2.5mg/dl in male and 1.0-2.5mg/dl in female) </plain></SENT>
<SENT sid="7" pm="."><plain>The patients were allocated standard treatment or intensive multifactorial treatment </plain></SENT>
<SENT sid="8" pm="."><plain>Intensive treatment was a stepwise implementation of behavior modification, pharmacological therapy targeting <z:e sem="disease" ids="C0020456" disease_type="Disease or Syndrome" abbrv="">hyperglycaemia</z:e>, <z:hpo ids='HP_0000822'>hypertension</z:hpo>, <z:e sem="disease" ids="C0242339" disease_type="Disease or Syndrome" abbrv="">dyslipidaemia</z:e>, and <z:hpo ids='HP_0000093'>proteinuria</z:hpo> </plain></SENT>
<SENT sid="9" pm="."><plain>The primary outcome is the <z:hpo ids='HP_0000093'>proteinuria</z:hpo> in protocol A and the composite endpoint of time to the first occurrence of doubling of serum <z:chebi fb="0" ids="16737">creatinine</z:chebi>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ESRD</z:e> (the need for <z:hpo ids='HP_0011010'>chronic</z:hpo> dialysis, or renal transplantation) or <z:hpo ids='HP_0011420'>death</z:hpo> in protocol B </plain></SENT>
<SENT sid="10" pm="."><plain>The follow-up period is 5 years and the study ends in 2014 </plain></SENT>
</text></document>